Filip Van den Wyngaert brings over 15 years of experience leading innovation and brand development across the full product lifecycle—from clinical development through to acquisition, commercialization, and global launch.
Notably, he led the asset strategy for Caplacizumab (Cablivi), guiding it from clinical proof of concept to acquisition and successful global launch with Sanofi. In recent years, Filip has held senior roles as a global brand lead and local business unit head in the rare disease space, working across key markets in Boston (US) and Frankfurt (DACH).
He holds a Master’s degree in Biomedical Sciences from the University of Antwerp, Belgium.
